Objective. Glucocorticoid (GC)-related adverse events greatly contribute to the outcome in giant cell arteritis (GCA). CYC was investigated as a steroid-sparing agent in GCA.
Introduction
Giant cell arteritis (GCA) is a large and medium-sized vessel vasculitis characterized by vascular inflammation with formation of granulomatous lesions in the vascular wall and subsequent increased risk of ischaemia, rupture and fatal bleeding [1, 2] . Activation of adventitial dendritic cells initiates and maintains T-cell responses in the artery and breaks tissue tolerance in the perivascular space [3] .
Glucocorticoids (GCs) at high doses are the cornerstone of treatment in GCA [4] . However, patients with GCA are usually aged >60 years, suffer from co-morbidities, and many of them require GC therapy for a long time [5] . In this setting, the outcome is frequently determined by GCrelated adverse events (AEs) [5] , thus a GC-sparing immunosuppressive therapy is required [6] . There is limited evidence of the efficacy of MTX [7] , AZA, anti-TNF-a [811] or anti-IL-6 treatment [1214] as steroid-sparing agents in GCA. Notably, some of these agents (i.e. MTX, infliximab) have been formally tested in randomized controlled trials, and MTX even in a meta-analysis [15, 16] . While MTX has a significant but modest effect, the existing evidence does not support the efficacy of infliximab [17] . CYC may be of value in the treatment of systemic vasculitis, including large vessel arteritis [6] . Besides the cytotoxic effects of CYC on lymphocytes, the immunomodulatory effects of low-dose CYC (also called metronomic CYC) have been shown in the oncology setting in recent years [18] . Based on preliminary, favourable experience [19] , CYC was used in 19 GCA cases in order to induce clinical response and minimize steroid doses in GC resistant cases, in patients relapsing despite medium to high doses of GC, and in patients with a very high risk of GC-related side effects. Of note, histopathological and immunohistochemistry analyses focusing on the expression of IFN-g and IL-17 in temporal artery biopsies [20] were also performed.
Patients and methods

Demographic and clinical data
We retrospectively analysed 19 patients referred to our centre from 2003 to 2011, diagnosed with GCA based on ACR criteria [21] and treated with CYC. Data regarding clinical diagnosis and history, laboratory assessment, histopathological and instrumental tests performed to confirm the diagnosis of GCA were collected. In patients in whom temporal artery biopsy was not performed (4 of 19, due to patient refusal), the remaining four of five ACR classification criteria for GCA were satisfied. Table 1 shows the demographic and clinical characteristics of the patients at onset of the disease.
The patients were 16 females and 3 males, with a mean (S.D.) age at disease onset of 70.11 (7.94) years (range 5880 years). All patients presented with headache at onset; PMR was associated with GCA in 13 of the 19 patients; 3 of the 19 had visual impairment related to GCA, one of them evolving in permanent unilateral visual loss; 7 of the 19 presented with fever and malaise; 1 of the 19 experienced worsening of hearing impairment; 1 of the 19 presented with upper limb claudication and absent radial pulse. All the patients had increased inflammatory markers at presentation (ESR and/or CRP) [mean (S.D.), median (range): ESR 57.9 (26.7) mm/h, 54 (22108) (normal value 215 mm/Ih); CRP 77.2 (62.1) mg/l, 58.0 (7.6210.0) (normal value 05 mg/l)].
Co-morbidities were the following: arterial hypertension in 12, type 2 diabetes mellitus in 8, osteoporosis in 7, dyslipidaemia in 7, chronic vascular encephalopathy or positive history for cerebrovascular events in 6, ischaemic cardiopathy in 5, arrhythmias in 3 and glaucoma in 2 of the 19 patients (Table 1) . Anti-platelet or anticoagulant therapy was already ongoing or was started at the time of diagnosis of GCA in 17 and 2 of the 19 patients, respectively.
Inclusion criteria
Inclusion criteria were represented by the presence of at least one of the following three points:
(1) resistance to GC, i.e. persistence of both symptoms and elevated CRP and/or ESR after induction with 1 mg/kg/day of prednisone given for at least 1 month; (2) disease relapse during high-to medium-dose GC therapy (0.31 mg kg/day of prednisone); and (3) unacceptable risk of GC toxicity, i.e. diabetes mellitus treated with insulin and/or oral anti-diabetic drugs, severe osteoporosis with previous bone fractures, uncontrolled arterial hypertension, ischaemic cardiopathy and cerebrovascular events.
Treatment plan CYC was planned in oral administration starting at the dose of 1.52 mg/kg/day at breakfast for 312 months. The initial CYC dose was reduced by 25% in patients with a glomerular filtration rate <60 ml/min or >65 years of age [22] . Concomitant daily oral mesna (diluted in juice, with 1:1 ratio with CYC) was used to prevent bladder damage. Patients were treated with CYC until clinical manifestations disappeared and laboratory inflammatory tests normalized, and for a maximum of 12 months. At least 3 months of CYC treatment were planned, unless treatment was not tolerated in individual cases, where a CYC treatment of <3 months but at least 1 month was accepted. Concomitant GC therapy in CYC-treated cases was planned as follows:
(1) medium to high GC dose (0.31 mg/kg/day of prednisone or equivalents) for at least 2 weeks in resistant/relapsing cases; (2) low to medium GC doses (<0.3 mg/kg/day of prednisone) in patients with a very high risk of GCrelated side effects and high cumulative GC dose.
After CYC suspension, MTX 1020 mg/week was employed as maintenance therapy.
Outcome measures
Efficacy of CYC was defined as both the complete disappearance of the symptoms related to GCA and the normalization of inflammatory markers. Relapse was defined as both the recurrence of GCA symptoms and/or PMR, and positive inflammatory markers.
Histopathological analyses
Collection of samples
Diagnostic temporal artery biopsies were performed in 15 of the 19 patients to establish a GCA diagnosis and all were available for pathological studies. Temporal artery sample sections from patients with non-specific manifestations but with normal histological findings were used as controls. Samples were fixed in 10% neutral buffered formalin and then paraffin embedded. Four-micrometre sections were cut and mounted on adhesive glass slides. To detect antigen expression in paraffinembedded sections, antigen retrieval procedures were performed, incubating sections in citrate buffer (10 mM, pH 6.0) at 98 C for 1 h. One patient was asked and gave consent to repeated temporal artery biopsy at the end of the third month of CYC treatment.
Immunohistochemistry: detection of cytokine-producing cells IL-17 and IFN-g expression were examined using polyclonal anti-IL-17 antibody (SC-7927; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and anti-IFN-g antibody (SC-8308; Santa Cruz Biotechnology) with a single-stain, immuno-peroxidase technique using 3,3 0 diaminobenzidine as chromogen.
Paraffin-embedded sections of temporal artery biopsies were treated in xylene and rehydrated in a gradient of ethanol. Endogenous peroxidase activity was blocked by incubation for 20 min with 3% H 2 O 2 solution. Sections were incubated with 2 mg/ml rabbit polyclonal anti-IL-17 or 1.3 mg/ml rabbit polyclonal anti-IFN-g for 60 min at room temperature; primary antibody was omitted in negative control sections. Polymer visualization reagent EnVision/HPR, rabbit/mouse (K5007; Dako A/S, Glostrup, Denmark) was used and 3,3 0 -diaminobenzidine was used as chromogen. Samples were also stained for CD3, CD4, CD8 and CD68 to clarify the phenotype of IL-17-and IFN-g-producing cells.
Results
CYC dose and regimen, GC dose at the beginning of CYC therapy and tapering, and clinical outcome and follow-up are shown in Table 2 .
Efficacy of CYC
Patients starting CYC ab initio were 4 of 19, while 15 of the 19 patients started CYC after GC monotherapy (Table 2 ). Of the latter 15 patients, 5 were refractory to GC, while 10 relapsed during GC tapering. The median dose of CYC was 100 mg/day (range 75150) ( Table 2) .
Overall, efficacy of CYC (both clinical and laboratory, as defined) was observed in 15 (78.9%) of the 19 patients.
The rate of response was similar in the group of patients starting CYC with high doses of GC and the group of patients starting CYC with low to medium doses of GC (8/10 vs 7/9, P = 0.66, Fisher's exact test).
Concerning the duration of CYC therapy, this was 5.2 (3.6) months [mean (S.D.)] ( Table 2 ). In particular, CYC was administered: (i) for >3 months in 10 (52.6%) of the 19 patients, with response in 9 of the 10 patients; (ii) for 3 months in 5 (26.3%) of the 19 patients, with response in 4 of the 5 patients, and suspension for inefficacy and side effects in the remaining patient; and (iii) for <3 months in 4 (21%) of the 19 patients with efficacy in 2 of the 4 patients, and suspension for inefficacy in 1 of the 4 patients and for side effects in 3 of the 4 patients ( Table 2 and 3) .
Follow-up after CYC
The follow-up after the completion of CYC treatment varied from 1 to 100 months ( Table 2) . A follow-up 56 months after CYC was available in 13 of the 15 patients, and a follow-up 512 months after CYC was available in 11 of the 15 patients. Remission 56 months was seen in 12 of the 13 responders, and remission 512 months was seen in 10 of the 11 responders.
MTX 1020 mg/week was employed immediately after the completion of CYC, as maintenance therapy, in 14 of the 15 responder patients, and was not tolerated in 1 of the 14 patients (stopped after 1 month because of nausea). In contrast, MTX after CYC was not advisable in 1 of the 15 patients because of aplastic crisis during CYC (see 'Tolerability' section and Table 3 ). Relapse occurred in 4 (26.7%) of the 15 patients responding to CYC. Three relapses occurred after a very long follow-up after CYC suspension (i.e. >24 months) and one relapse occurred 1 month after the completion of CYC therapy. CYC was given to two relapsed cases, and was again effective in both.
GC sparing effect
GCs were suspended in 6 (40%) of the 15 responders to CYC. In the remaining nine responders, GC dosage was continued at a dose 45 mg/day of prednisone. Suspension of GC or reduction to 45 mg/day of prednisone occurred in 10 (66.7%) of the 15 patients within the first 6 months of follow-up after the beginning of CYC. When considering the 15 responder patients, the mean time to GC suspension or reduction to 45 mg/day of prednisone was 4.5 (3.5) months (range 114). Tolerability Table 3 shows the AEs registered for each patient, along with the grade of severity according to common terminology criteria for AEs (CTCAEs), timing of onset of AE since CYC was started, changes needed in CYC therapy and outcome of each AE. We registered 10 AEs in nine patients, two of which were severe (grade 54). One patient had acute hepatitis due to CYC treatment after 1 month of therapy (biopsy proven, other concomitant causes excluded), with fatal liver failure. Three haematological AEs were registered: one aplastic crisis (grade 4) complicated with oral and oesophageal candidosis (grade 3), resolved after CYC suspension; one mild pancytopenia (grade 2 leucopoenia, grade 1 anaemia and thrombocytopenia), resolved after CYC dose reduction; and one isolated mild neutropenia (grade 1), resolved after CYC dose reduction. One patient developed grade 3 oral mucositis, resolved after CYC suspension. One infection of the upper airways (grade 2) was recorded, requiring transitory suspension of CYC. One patient experienced pruritus (grade 2), not related to mesna, and recovered after CYC suspension. One patient developed mild hypertransaminasaemia (grade 1), resolved with dose reduction of CYC. One patient experienced alopecia (grade 2) after 6 months of CYC treatment, which resolved after CYC suspension. Overall, CYC suspension was required in five patients, CYC dose reduction was sufficient for the recovery of AE in three cases and CYC transient suspension was necessary in one case.
Histopathological analyses and clinical correlation
Diagnostic temporal artery biopsy was available in 15 of the 19 patients. The median post-fixation specimen length was 1.2 cm (range 0.84). Positive biopsies were characterized by an inflammatory infiltrate observed in the adventitial and periadventitial lamina. The infiltrate was mainly composed by CD3-positive lymphocytes and CD68-positive histoid-like multinucleated giant cells sometimes aggregated in microgranulomas. Nine (60%) of the 15 biopsies were positive for temporal arterial vasculitis. Biopsy was performed without ongoing GC in 8 (53.3%) of the 15 patients. In the remaining seven patients, time between treatment start with GC and biopsy was 2 months (range 148), with no difference between positive and negative biopsy (data not shown). PMR preceded GCA onset in 4 of the 15 biopsied patients, 1 of the 9 patients with positive biopsy (11.1%) and 3 (50%) of the 6 patients with negative biopsy. Inflammatory infiltrates characterized by the presence of IFN-g producing T lymphocytes at baseline before CYC was shown in 7 (77.8%) of the 9 patients, while IL-17 was detected in 6 (66.7%) of the 9 patients (Table 1) . By the staining of consecutive sections, the IFN-g-positive or IL-17-positive staining corresponded to the infiltrating T cells (CD3 positive). One patient (patient 15) agreed to repeat temporal artery biopsy at the end of the third month of CYC therapy. At the end of 3 months of CYC, complete disappearance of inflammatory infiltrates was observed in this patient, together with the disappearance of local expression of IFN-g in the repeated biopsy (Fig. 1) . MTX 20 mg/week as maintenance was started in this patient after the completion of 3 months of CYC.
Discussion
The present reported experience demonstrates the efficacy of CYC in the largest published cohort of GCA patients treated with this drug. CYC was effective in $80% of our cases and allowed a very long-term remission in the 90% of patients with adequate follow-up. Moreover, CYC allowed a reduction of GC to very low doses, or to suspend them, in nearly all the responder patients within the first 6 months of CYC treatment. Interestingly, CYC was used without high doses of GCs in 9 of the 15 patients, and was effective in 7 of these 9 patients, supporting the efficacy of CYC itself in GCA.
The efficacy of CYC is well documented in ANCA-related systemic vasculitis [23] , while very few published data are available on CYC therapy in GCA [19, 24] . The clinical efficacy of induction therapy with CYC in GCA has been recently supported by concomitant PET/CT examination in the series from Henes et al. [24] , where CYC was employed in 10 cases of large-vessel vasculitis. From the clinical point of view, despite the differences in the route of administration of CYC and in the type of GCA (4 of the 6 with large vessel GCA from Henes et al. [24] vs 2 of the 19 in our series), our results are in line with those observed by Henes et al. [24] .
After induction of remission with CYC, we maintained remission with MTX. We chose this treatment option, again, to spare GC, although the efficacy of MTX in GCA is not well established [6] . Relapse of GCA occurred in few patients, usually more than 24 months after CYC therapy, and CYC was again effective when administered.
The efficacy of CYC in GCA was also reinforced by histopathologic data in a patient who underwent a second temporal artery biopsy 3 months after the start of CYC. Although this observation does not represent a proof of concept of the efficacy of CYC, due to the segmental nature of the disease, the complete resolution of the artery wall inflammation correlated with the complete clinical recovery of the patient as well as with the resolution of the systemic inflammatory state. GCA is a T cell-dependent disease [25] , and a switch of adventitial DCs from being nonstimulatory to T cell activating emerges as a critical event in the initiation of vasculitis [2629] . Two distinct T cell subsets have been recently implicated in the pathogenesis of GCA, through adventitial dendritic cells activation, i.e. T helper 1 (Th1) cells, producing IFN-g and modulating macrophage activation and functions, and Th17 cells producing IL-17 [30] . While Th17 cells are efficiently targeted by GCs, Th1 cells seem to be resistant to GCs [20] . CYC was effective in GC-resistant GCA in this study, and then might effectively target IFN-g-positive T cells, which were documented in almost 80% of the studied samples. In addition, oral rather than pulsed CYC might modulate dendritic cells upstream to T cell activation, as recently hypothesized in oncology, where prolonged, frequently administered oral low-dose metronomic chemotherapy seems to be a promising antiangiogenic antitumor strategy [31, 32] .
There were limitations of this study. The main limitation is its retrospective nature, which is also highlighted by the large variation both in the treatment duration and in the follow-up. However, our findings may be of interest in the light of the present lack of GC-sparing drugs in GCA. In addition, the long-term follow-up herein reported in the majority of the patients is important to support the longterm efficacy of CYC induction (usually employed for 46 months) rather than prolonged therapy.
Secondly, GCA was biopsy proven in 9 of the 15 patients included. Such a low rate of positive biopsies (60%) may be related to the time when the procedure was performed in patients with a negative result (i.e., just before CYC therapy, and after prolonged GC treatment in patients with PMR preceding GCA onset) rather than to an inadequate length of the segment of temporal artery in this study [33] . Otherwise this raises the question of whether patients who failed to respond to high-dose GC had a mimicking disease including necrotizing vasculitis, which sometimes may involve cranial arteries and may convey cranial and polymyalgic symptoms [34, 35] . However, no patient met the classification criteria or deserved a clinical diagnosis of a systemic vasculitis other than GCA, e.g. panarteritis nodosa, both at the time of diagnosis and in the subsequent follow-up.
Thirdly, the rationale for testing CYC in patients with GCA, a disease of aged people, with very low disease-related early mortality, may be questionable based on the tolerability profile observed in this study, where four grade 35 AEs and one death occurred. However, we avoided high-dose GC, and likely avoided other side effects in this way. CYC was generally well tolerated in most of our patients despite their comorbidities and advanced age, and the CYC safety profile appears acceptable even in ANCA-positive vasculitis in elderly patients [22] . AEs usually occurred in the first 4 months after CYC administration, and all but one resolved after CYC dose reduction or suspension. Furthermore, CYC was suspended and MTX was introduced as soon as GCA was controlled, to avoid further CYC treatment. One death occurred due to CYC-related acute hepatitis. While a possible increase in CYC-induced hepatitis must be considered in GCA, this CYC side effect appears rare in the literature, as well as in the elderly [22, 23] , and for www.rheumatology.oxfordjournals.org this reason we think that there are insufficient data, at present, to definitely avoid CYC therapy in GCA.
Of note, the most relevant AEs (i.e. acute hepatitis and aplastic crisis) occurred early, i.e. in the first month of CYC therapy in this study. Thus we recommend weekly laboratory monitoring of blood tests and renal and hepatic function in the first month. Furthermore, lower CYC doses (1 mg/kg/day) might be considered in further investigation.
In conclusion, CYC therapy, followed by MTX maintenance therapy, may be considered for GC-resistant GCA, in GCA requiring a prolonged medium to high dose of GC therapy, and in patients at very high risk of GC-related side effects in order to reduce the concomitant GC dose. Close monitoring during CYC administration is mandatory. CYC might effectively target the IFN-g-driven GC-resistant inflammation. The inflammatory infiltrate (A and B; haematoxylin & eosin, magnification Â200 and Â100, respectively), the infiltrate of CD3-positive cells (C and D; magnification Â200 and Â100, respectively) and the local production of IFN-g (E and F; magnification Â200 and Â100, respectively) in patient 15 before CYC. The complete absence of inflammatory infiltrates, CD3-positive cells and IFN-g production in the temporal artery wall at the end of 3 months of CYC are shown in the panels on the right (B, D, F). The black arrows indicate the inflammatory infiltrate in the elastic lamina of the temporal artery wall. Optical magnification of the inflammatory infiltrate was included in the sections on the left.
Rheumatology key messages
. Oral CYC may be effective in GCA patients at very high risk of GC toxicity. . Oral CYC may be considered in GCA patients requiring prolonged medium-to high-dose GC. . Close monitoring of possible CYC-related side effects is mandatory.
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